VFA
AKRO

Valeo Financial Advisors’s Akero Therapeutics AKRO Stock Holding History

Valeo Financial Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50
Closed -$1K – 1784
2019
Q4 		$1K Buy
+50
New +$1.03K ﹤0.01% 1512

Other funds holding AKRO

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Valeo Financial Advisors's AKRO Position: Q1 2020 in Review

Valeo Financial Advisors sold out of Akero Therapeutics (AKRO) in Q1 2020, closing a stake of 50 shares — an estimated $1K sold.

Valeo Financial Advisors first reported a position in AKRO in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 67 funds tracked by Wall St. Rank hold AKRO as of Q1 2020.

  • Valeo Financial Advisors reported no remaining Akero Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Valeo Financial Advisors sold 50 Akero Therapeutics shares in Q1 2020, an estimated $1K.
  • Valeo Financial Advisors first reported a position in Akero Therapeutics in Q4 2019 and held it in 1 quarter.
  • Valeo Financial Advisors's Akero Therapeutics position peaked at $1K in Q4 2019.
  • 67 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2020.

Based on Valeo Financial Advisors's 13F filing for Q1 2020, filed 13 Apr 2020.